4D Biomaterials

4D Medicine is a private, pre-revenue biotech company founded in 2016, commercializing a novel bioabsorbable polymer technology called 4Degra®. Its core innovation lies in a material that offers an improved degradation profile, enhanced biocompatibility, and unique high-resolution 3D printing capabilities, enabling the creation of next-generation, patient-specific medical implants. The company is strategically advancing an initial product through FDA 510(k) clearance while building a pipeline, aiming to capture share in the global bioabsorbable biomaterials ($1bn) and medical devices ($6bn) markets through a hybrid business model of direct product development and partnerships.

Patented 4Degra® bioabsorbable polymer platform with an improved degradation profile, enhanced biocompatibility, and unique high-resolution 3D printing capability for creating patient-specific medical implants.

4D Medicine competes with large chemical companies supplying bioabsorbable polymers (e.g., Evonik, Corbion) and established medical device manufacturers with absorbable product lines (e.g., Johnson & Johnson, Stryker, Smith & Nephew). Its primary differentiation is the combination of its novel polymer chemistry with high-resolution 3D printing, aiming to create devices with superior regenerative properties rather than just structural fixation.